GU Cancer

NRG-GU013

The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate Cancer

---

URCC 19185

Multicenter Randomized Controlled Trial comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)

---

A032103

MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer

---

EAY191 (ComboMATCH) **If biopsy needed, TBD at MBMC**

Molecular Analysis for Combination Therapy Choice

---

S2200

A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)

---

ALLIANCE A212102 **AT MBMC ONLY** ***Participant Engagement Portal (PEP) is Closed to New Patient Registration as of 9/15/25*** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**

Blinded Reference Set For Multicancer Early Detection Blood Tests

---

NCI 10323

Cancer Moonshot Biobank Research Protocol

---

S2013: I-CHECKIT ***Only Cohort 2 is open to enrollment***

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

---

S1931

Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

---

A151804

Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

---